Is Tesamorelin FDA approved?

Tesamorelin is FDA approved (FDA status current as of 2010-11-10). This regulatory status is provided for research and educational context only.

How is CJC-1295 (without DAC) administered in research settings?

In research settings, CJC-1295 (without DAC) is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Tesamorelin administered in research settings?

In research settings, Tesamorelin is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›CJC-1295 (without DAC) vs Tesamorelin

Peptide Comparison

CJC-1295 (without DAC) vs Tesamorelin

Name: CJC-1295 (without DAC) vs Tesamorelin — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

CJC-1295 (without DAC)

CJC 1295

Fat LossResearch Only

Half-life: ~30 minutes

501 providers listed

Full CJC-1295 (without DAC) profile →

Tesamorelin

Egrifta

Fat LossFDA ApprovedPrescription

Half-life: 26–38 minutes

296 providers listed

Full Tesamorelin profile →

Bottom line

Tesamorelin is FDA-approved, while CJC-1295 (without DAC) is nomination withdrawn — the clearest structural difference between them.

Quick Verdict

CJC-1295 (without DAC)

Half-life

~30 minutes

Tesamorelin

Half-life

26–38 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Tesamorelin
Further along in FDA review	Tesamorelin
More provider options (501 vs 296)	CJC-1295 (without DAC)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

CJC-1295 (without DAC)

Tesamorelin

Mechanism Family

GH / IGF Axis

Half-life

~30 minutes

26–38 minutes

FDA Status

nomination withdrawn

approved

Admin Routes

subcutaneous

Availability

Research Only

Prescription

Providers

501 listed

296 listed

FDA Update

—

Nov 2010

Avail. Notes

GHRH analog — the truncated 1-29 form (Mod GRF 1-29), WITHOUT the Drug Affinity Complex (DAC). No FDA approval; not on the FDA 503A bulks list. WADA prohibited (S2) as a growth-hormone-releasing factor. Sold as a research chemical only.

FDA-approved GHRH analog. Brand: Egrifta SV (NDA 022505, Nov 2010). Indicated for excess abdominal fat in HIV lipodystrophy. Prescription only. Daily subcutaneous injection.

Research Evidence

CJC-1295 (without DAC)

RCT · 3 key studies · most recent 2026

Tesamorelin

RCT · 7 key studies · most recent 2026

Research Citations

CJC-1295 (without DAC)

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…

RCT1997 · Journal of Clinical Endocrinology and Metabolism

Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…

Review2026 · JBJS Rev

Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…

Tesamorelin

RCT2012 · Arch Neurol

Effects of growth hormone–releasing hormone (tesamorelin) on cognitive function in adults with MCI and health…

RCT2010 · Journal of Acquired Immune Deficiency Syndromes

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with exce…

RCT2010 · J Clin Endocrinol Metab

Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 RCTs

Case series2026 · Clin Infect Dis

Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highli…

+3 more

About CJC-1295 (without DAC)

CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.

Research Areas

GH and IGF-1 elevationsustained GHRH receptor agonismbody composition supportrecovery enhancementGH axis restoration

About Tesamorelin

Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.

Research Areas

FDA-approved GHRH analog for HIV-associated lipodystrophy (Egrifta / Egrifta SV)visceral fat reduction via GH/IGF-1 axis — strongest clinical evidence of any fat-targeted peptide2 mg/day subcutaneous injection — structured monthly dosing in approved indicationIGF-1 elevation monitoring relevant — considered in metabolic syndrome and diabetes contexts

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

CJC-1295 (without DAC)

Warnings & Cautions

Active malignancy — caution (GH/IGF-1 is mitogenic)Pregnancy — cautionKnown hypersensitivityGlucose intolerance / insulin resistance

Class-based (investigational)

Suggested Monitoring

IGF-1Fasting glucoseHbA1cInsulin

Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Tesamorelin

Absolute Contraindications

Disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation, or head trauma)Active malignancy (any prior cancer must be inactive and treatment complete)PregnancyKnown hypersensitivity to tesamorelin or mannitol

Warnings & Cautions

Elevated IGF-1Glucose intolerance / new or worsening diabetesFluid retentionNot for use in children with open epiphyses

Source: FDA label

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Regulatory Notes

global — WADA

This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.

source

Used Together?

CJC-1295 (without DAC)

Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.

Price (per mg)

CJC-1295 (without DAC)

$7.80/mg

$6.60 – $10.88 range

63 vendors

View price index →Find providers →

Tesamorelin

$7.86/mg

$6.32 – $10.57 range

73 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

CJC-1295 (without DAC)

501 listed

Browse directory →

Providers offering

Tesamorelin

296 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated October 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). CJC-1295 (without DAC) vs Tesamorelin — Per-mg Price Comparison. Retrieved October 26, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/tesamorelin

https://peptidebase.io/peptides/compare/cjc-1295/tesamorelin Methodology License Download JSON Download CSV